Segall Bryant & Hamill LLC Takes $5.56 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Segall Bryant & Hamill LLC acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 56,942 shares of the medical equipment provider’s stock, valued at approximately $5,558,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Janus Henderson Group PLC lifted its holdings in Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after acquiring an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC grew its holdings in shares of Lantheus by 79.9% during the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after buying an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after acquiring an additional 435,445 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Lantheus in the 4th quarter valued at about $36,183,000. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Lantheus by 1,196.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider’s stock valued at $32,817,000 after purchasing an additional 310,301 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

Shares of LNTH stock opened at $73.60 on Friday. Lantheus Holdings, Inc. has a one year low of $69.12 and a one year high of $122.83. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The stock has a market cap of $5.09 billion, a PE ratio of 20.91 and a beta of 0.12. The stock has a 50-day moving average of $79.04 and a 200-day moving average of $89.57.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same period last year, the company earned $1.69 EPS. The company’s revenue was up .8% compared to the same quarter last year. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director owned 318,650 shares in the company, valued at $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. B. Riley dropped their price objective on Lantheus from $122.00 to $109.00 and set a “buy” rating on the stock in a report on Monday, June 23rd. Wall Street Zen upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. William Blair reaffirmed a “market perform” rating on shares of Lantheus in a research report on Wednesday. Finally, Truist Financial dropped their price objective on Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.20.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.